Gilead Sciences Inc logo

GILD - Gilead Sciences Inc News Story

$60.21 -0.3  -0.6%

Last Trade - 9:00pm

Sector
Healthcare
Size
Large Cap
Market Cap £58.65bn
Enterprise Value £62.74bn
Revenue £17.13bn
Position in Universe 131st / 6436

BRIEF-Innovation Reports Data From Lab Supporting Brilacidin As Potential Treatment For SARS-CoV-2

Tue 15th September, 2020 2:17pm
Sept 15 (Reuters) - Gilead Sciences Inc  GILD.O :
    * INNOVATION PHARMACEUTICALS  -  REPORTS ADDITIONAL DATA
FROM LAB
SUPPORTING BRILACIDIN AS POTENTIAL TREATMENT FOR SARS-COV-2
    * INNOVATION PHARMACEUTICALS INC - LABORATORY TESTING OF
BRILACIDIN FOR COVID-19 IN COMBINATION WITH REMDESIVIR REDUCES
VIRAL LOAD BY NEARLY 100%

Source text for Eikon:  ID:nGNX3Fsf9R 
Further company coverage:  GILD.O 

 ((Reuters.Briefs@thomsonreuters.com;))
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.